Intelligent Bio Solutions (INBS) Equity Income (2022 - 2023)
Intelligent Bio Solutions (INBS) recorded quarterly Equity Income of $44488.0 in Q4 2023, down 66.1% quarter-over-quarter from $131250.0 in Q3 2023, and down 97.52% on a YoY basis from $1.8 million in Q4 2022.
Intelligent Bio Solutions (INBS) Equity Income (2022 - 2023) Analysis & Trends
Intelligent Bio Solutions' Equity Income history runs 2 years deep, the most recent figure standing at $44488.0 for Q4 2023.
- In Q4 2023, Equity Income fell 97.52% year-over-year to $44488.0; the TTM figure through Mar 2024 stood at $267225.0 (changed N/A YoY), while the FY2023 annual figure was $2.2 million, changed N/A from the prior year.
- Equity Income was $44488.0 for Q4 2023 at Intelligent Bio Solutions, down from $131250.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of $1.8 million in Q4 2022 to a low of $44488.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.68 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Intelligent Bio Solutions | 12.67 Mn | 11.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 44,488.00 |
| Sep 30, 2023 | 131,250.00 |
| Jun 30, 2023 | 91,487.00 |
| Mar 31, 2023 | 269,787.00 |
| Dec 31, 2022 | 1.79 Mn |